Phase 3 N=817 Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia
Leukemia
Primary: Progression-free Survival (PFS) — 981.0; 1212.0 Days — p=<.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=44 Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Leukemia · Lymphoma
Primary: Number of Participants With Complete Response (CR) — 14 participants
Phase 2 N=105 Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis
Chronic Lymphocytic Leukemia
Primary: Change in Gene Expression Post Chemo — 30; 50 Percent change in cells
Phase 2 N=60 Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)
Leukemia, Lymphocytic, Chronic, B-Cell
Primary: Complete Response (CR) — 8.3 Percentage of participants with CR — p=0.014
Phase 2 N=12 Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
B-cell Chronic Lymphocytic Leukemia · Refractory Chronic Lymphocytic Leukemia
Primary: Number of Patients With Confirmed Objective Status of Complete Response (CR), Complete Clinical Response (CCR), Nodular Partial Response (nPR), or Partial Response (PR)…
Phase 2 N=17 Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)
Leukemia · Lymphoma
Primary: Participants With Objective Response — 0; 1; 13 Participants
Phase 2 N=15 Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia
Leukemia · Lymphocytic · Chronic
Primary: Response Rate — 0; 1; 3; 11 Participants
Phase 2 N=14 Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Primary: Overall Response Rate — 6; 7 Participants
Phase 2 N=23 Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic · Chronic Lymphocytic Leukemia · Small Lymphocytic Leukemia
Primary: Participants With Complete Remission (CR) at 24 Months — 3 Participants
Phase 2 N=199 Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
B-cell Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma · Diffuse Well-differentiated Lymphocytic Lymphoma
Primary: Number of Subjects With Adverse Events — 199 Participants
Phase 2 N=68 Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Leukemia · Lymphoma
Primary: Complete and Overall Response Rate — 50.0; 33.3; 93.8; 96.7 percentage of patients
Phase 3 N=269 Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: PFS (Progression Free Survival) — NA; 18.9 Months — p=<0.0001
Phase 2 N=26 Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age
Chronic Lymphocytic Leukemia · Leukemia
Primary: Best Response — 20; 3; 3 Participants
Phase 2 N=10 Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Primary: Response Rate [Complete Remission (CR) +Complete Remission / Incomplete (CRi) + Nodular Partial Remission (nPR) + Partial Remission (PR)] Based on International Workshop…
Phase 2 N=15 Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
B-Cell Chronic Lymphocytic Leukemia · B-Lymphocytic Leukemia, Chronic · Chronic Lymphocytic Leukemia
Primary: Number of Participants With Complete Response of the Combination of Ibrutinib, Fludarabine, and Pembrolizumab in Patients With High-risk and/or Relapsed/Refractory…
N/A N=67 A Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic Leukemia
Lymphocytic Leukemia, Chronic
Primary: Percentage of Participants With Adverse Events (AEs) — 89.6 percentage of participants
Phase 2 N=50 Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer
Leukemia · Lymphoma
Primary: Overall Response — 11; 23; 4; 5 participants
Phase 3 N=269 Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Progression Free Survival (PFS) Based on Investigator Assessment — 106.9; 15.0 months — p=< 0.0001
Phase 2 N=144 A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion
Chronic Lymphocytic Leukemia With 17p Deletion · Small Lymphocytic Lymphoma With 17p Deletion
Primary: Overall Response Rate — 77.8 % of participants with response by PI
Phase 2 N=16 Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission
Lymphoid Leukemia in Remission · Stage I Chronic Lymphocytic Leukemia · Stage II Chronic Lymphocytic Leukemia
Primary: Probability of Progression-free Survival (PFS) — 52 percentage probability
Phase 2 N=132 Safety of PCI-32765 in Chronic Lymphocytic Leukemia
B-cell Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) — 116; 11 Participants
Phase 1 N=37 BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)
Leukemia, Lymphocytic, Chronic, B-Cell
Primary: Number of Patients With Dose-Limiting Toxicities Adverse Events (DLTs) — 0; 0; 0; 0 Participants
Phase 2 N=102 Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL
Leukemia
Primary: Response Rate — 55.2 percentage
Phase 2 N=33 Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia
Leukemia
Primary: Number of Confirmed Responses (Complete or Partial Response Noted as the Objective Status for a Duration of at Least 2 Months) at 6 Months — 31 Participants
Phase 3 N=351 CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)
Lymphocytic Leukemia, Chronic
Primary: Progression-free Survival (PFS) — 16.5; 11.1 Months — p=<0.0001
Phase 2 N=100 A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia.
Lymphocytic Leukemia, Chronic
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) — 99 percentage of participants
Phase 2 N=102 Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
B-cell Chronic Lymphocytic Leukemia · Stage I Chronic Lymphocytic Leukemia · Stage II Chronic Lymphocytic Leukemia
Primary: Number of Participants With a Complete Response After Treatment With Fludarabine & Rituximab Followed by Alemtuzumab — 38 participants
Phase 2 N=59 Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Overall Participant Response Rate: Percentage of Participants With Complete + Partial Response According to Revised National Cancer Institute-sponsored Working Group…
Phase 4 N=357 A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)
Lymphocytic Leukemia, Chronic
Primary: Percentage of Participants Achieving Confirmed Complete Response (CR) According to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 Guidelines in the…
Phase 2 N=49 Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
Leukemia · Lymphoma
Primary: Overall Objective Response — 10; 5; 26; 4 Participants